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Abstract
BACKGROUND: Many studies have shown low Vitamin-D level as a risk factor for autoimmune diseases, especially 
multiple sclerosis and thyroid disease. Graves’ disease (GD) is an autoimmune disease caused by autoantibodies 
that stimulate thyroid-stimulating hormone (TSH) receptors by increasing thyroid hormone synthesis and secretion. 
Several studies report that many patients with autoimmune thyroid disease including GD have low Vitamin-D status.
AIM: The objective of the study was to evaluate the effect of Vitamin-D supplement on GD patients on improvement 
in thyroid hormone levels.
METHODS: Open random clinical trial was conducted in GD patients to determine changes in thyroid hormone to 
achieving normal levels between those receiving methimazole plus Vitamin-D supplementation compared with those 
who only received methimazole. Patients were checked for TSH receptor antibody, thyroid profile and Vitamin-D 
level before treatment and rechecked for thyroid profile and Vitamin-D level 3 months after treatment. t-test used to 
compare the drug efficacy (p < 0.05) in two groups.
RESULTS: From 25 children with GD accompanied by Vitamin-D deficiency with an average value of Vitamin-D 
was 16 ng/mL. GD children who receive methimazole with Vitamin-D supplement had elevated TSH levels in the 3rd 
month of therapy that was significantly different compared to GD children who received methimazole only (p = 0.00), 
and the increase of TSH was also followed by an increase in Vitamin-D levels.
CONCLUSION: All children with GD had Vitamin D deficiency, and the addition of Vitamin-D supplement to GD 
therapy would improve TSH faster than children who did not receive Vitamin-D supplement.
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Introduction
Graves’ disease (GD) is an organ-specific 
autoimmune disease characterized as overproduction 
of thyroid hormones in thyroid follicular cells resulting 
from the stimulation of circulating thyroid-stimulating 
hormone (TSH) receptor antibodies (TRAb) [1]. 
GD is the most common cause of thyrotoxicosis in 
children and has a higher incidence in women. GD 
is characterized by thyrotoxicosis, hyperthyroid, and 
ophthalmopathy [2].
1,25-Dihydroxyvitamin D [1,25(OH)2D, 
calcitriol] is a steroid hormone derived from Vitamin-D, 
which plays an important role in maintaining an adequate 
level of serum calcium and phosphorus [3]. Although the 
biological activities of Vitamin-D are mainly manifested 
in the regulation of calcium-phosphorus metabolism, 
studies in the past 30 years indicate Vitamin-D play an 
important role in the immune system. Many studies have 
shown that low levels of Vitamin-D contribute to GD and 
hashimoto thyroiditis (HT) and that combining Vitamin-D 
with anti-thyroid drugs or thyroid hormone contributes 
to the treatment of autoimmune thyroid disease (AITD) 
by suppressing the autoimmune reaction and reducing 
serum levels of thyroid autoantibodies [4].
Studies assess the addition of Vitamin-D in 
treatment of patients with GD in Japan report that the 
reduction in FT4 and FT3 levels was greater in the group 
receiving methimazole plus Vitamin-D supplements, 
and they suggest to concomitant administration of 
Vitamin-D is useful for treating hyperthyroidism in 
patients with GD [5].
Many studies in adults that correlated Vitamin-D 
levels with GD, but in children studies that correlated 
Vitamin-D and GD is very limited, so we conducted a 
clinical trial that investigated the relationship between 
Vitamin-D levels and GD.
Methods
This study was an open randomized clinical trial 
to measure the efficacy of Vitamin-D supplementation 
for treat GD patient in the pediatric endocrinology clinic 
of H. Adam Malik General Hospital Medan, periods in 
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May–December 2019. This study was approved by the 
Ethics Committee of Faculty of Medicine, Universitas 
Sumatera Utara (No. 394/TGL/KEPK FK USU-RSUP 
HAM/2019) in accordance with the principles of the 
Helsinki Declaration.
The inclusion criteria are children with GD 
and the parents willing to participate in the study are 
proven by signing an informed consent sheet. The 
exclusion criteria are GD patients with chronic kidney 
disease, chronic liver disease, and patients who 
receive any drugs that affect Vitamin-D levels, such as 
steroids, antiepileptics, methotrexates, INH (isoniazid), 
thiazides, antacids, calium channel blockers, and 
anticonvulsants. This study was approved by the Health 
Ethics Committee of the Faculty of Medicine, University 
of North Sumatra and the H. Adam Malik Hospital 
Medan Ethics Committee. All parents or guardians of 
patients have been informed and asked for consent to 
have their children involved in this study.
All patients who present with neck lumps 
were tested for TRAb, neck ultrasound, TSH, and 
FT4 to diagnose GD. Then, all samples that meet the 
inclusion and exclusion criteria were randomly divided 
using simple randomization into two treatment groups; 
Group I received methimazole (0.25–1 mg/kg/day) with 
Vitamin-D supplement (2000 IU/day) and Group II: 
received methimazole only (0.25–1 mg/kg/day). All 
sample reexamined after 2 months and 3 months 
treatment to assess improvement in thyroid hormone 
and Vitamin-D level. The efficacy is assessed using 
increase of TSH and decrease of FT4 level. Vitamin-D 
values were categorized as being deficient when 
<20 ng/L (50 nmol/L) and insufficient between 21 
and 29 ng/L (52.5–72.5 nmol/L), on the basis of 
Endocrinology society [6].
The data analysis is made using Statistical 
Package for the Social Sciences for Windows (SPSS) 
version 24.0, 2016, with a confidence interval at 95% 
and a significance rate p < 0.05. t-test was used to 
compare differences in the level of thyroid profile 
between Group I and Group II in this study.
Results
Study participants
There were 27 subjects met inclusion criteria in 
the period May–December 2019. Vitamin-D examination 
was incomplete in two patients, so 25 patients were 
included in the analysis, and then they are divided 
randomly into two treatment groups (Figure 1).
Basic characteristics samples in this study 
before intervention did not differ, with an average age 
of 13.5 years, the overall sample was female, and most 
of the samples had well nourished (Table 1).
Table 2 shows TRAb levels, thyroid profiles 
(TSH, FT4), and Vitamin-D levels in the 1st month before 
start therapy. We found that in GD patients where 
there was an increase in TRAb, decrease in TSH, and 
increase in FT4, accompanied by Vitamin-D deficiency, 
there were no significant differences between the two 
treatment groups for TRAb levels, thyroid profile, and 
Vitamin-D level.
Table 2: TRAb levels, thyroid profile, and Vitamin-D levels in 
the 1st month
Variables Group I (n=13) Group II (n=12) p*
TRAb positif (>1.75 IU/L), mean 20.4 22.4 0.05
Thyroid-stimulating hormone level, mean 0.04 0.05 0.98
FT4 level, mean 2.89 2.37 0.14
Vitamin-D deficient (<20 ng/L) mean 15.6 16.5 0.50
*t-test, TRAb: TSH receptor antibody.
In the 2nd month after therapy, there was 
an increase of TSH in Groups I who treated with 
methimazole and Vitamin-D supplement, and decrease 
of FT4 in both groups. The level of TSH and FT4 in both 
groups did not differ significantly. However, FT4 level 
in Group I was decrease more greater than Group 2 
(Table 3).
Table 3: Thyroid profile in the 2nd month
Variables Group I (n=13) Group II (n=12) p*
Thyroid-stimulating hormone level, mean 0.08 0.05 0.29
FT4 level, mean 2.5 2.2 0.24
*t-test.
In the 3rd month of treatment, both treatment 
groups experienced an increase of TSH, decrease of 
FT4, and increase of Vitamin-D level. Statistically, there 
were significant differences in the increase of TSH and 
Table 1: Baseline subject characteristics
Characteristics Treatment group
Group I (n=13) Group II (n=12)
Age (year), mean (SD) 13.8 13.2
Nutritional status, n (%)
Well nourish 10 (52.6) 9 (47.4)
Overweight 3 (50) 3 (50)
Sex, n (%)
Female 13 (50) 12 (50)
GD patients (n = 27)
Examination of TRAb, TSH, FT4, Vitamin-D
Eksklusi, inspection was
incomplete (n = 2)
Inklusi (n = 25)
Group I :
Methimazole + vitamin-D (n = 13)
Group II:
Methimazole (n= 12)
Reexamination (2nd month): TSH, FT4
(n = 13)
Reexamination (2nd month): TSH, FT4
(n = 12)
Reexamination (3rd month) : 
TSH, FT4, vitamin-D (n = 13)
Reexamination (3rd month) : 
TSH, FT4, vitamin-D (n = 12)
Figure 1: Study flow chart
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Vitamin-D levels between Group I who treated with 
methimazole with Vitamin-D supplement and Group 
II who treated with methimazole only, with p < 0.05 
(Table 4).
Table 4: Thyroid profile and Vitamin-D levels in the 3rd month
Variables Group I (n=13) Group II (n=12) p*
Thyroid-stimulating hormone Level, Mean 0.14 0.06 0.00
FT4 Level, Mean 2.33 2.17 0.56
Vitamin-D level, mean 23.8 17.9 0.00
*t-test.
Increase of TSH levels in the group who 
received methimazole with Vitamin-D was faster 
compared to the group who received methimazole 
without Vitamin-D (Figure 2).
Months
Group I
Group II
Figure 2: Thyroid-stimulating hormone comparison curves in the two 
treatment groups
Discussion
Vitamin-D receptors have been found in the 
immune system, reproductive system, endocrine system, 
muscles, brain, skin, and liver as well as bones, kidneys, 
and intestines; this proves that the role of Vitamin-D is 
not only limited to the skeletal system [7]. The function 
of Vitamin-D mainly in calcium-phosphorus metabolism, 
but a recent study shows that Vitamin-D also plays a 
role in the immune system [4]. Because Vitamin-D is an 
innate modulator and adaptive immunity, so Vitamin-D 
deficiency has a relationship with various autoimmune 
diseases [8]. Many studies have shown low Vitamin-D 
level as a risk factor of autoimmune diseases, especially 
multiple sclerosis and thyroid disease [9].
Thyroid disease is the most frequent 
endocrine disorder, including AITDs, namely, HT and 
GD, which occupy the main position around 5% of the 
population. AITDs are multifactorial diseases, where 
immunity influences gland infiltration by T and B cells 
and the production of specific autoantibodies, which 
are reactive to roid antigens (anti-thyroglobulin, anti-
thyroid peroxidase [thyroid peroxidase antibodies], and 
anti-TH receptors [TRAb]) [10]. In addition, Vitamin-D 
supplementation has a benefit effect on the treatment 
of AITD by reducing levels of thyroid antibodies and 
suppressing autoimmune reactions. A number of 
previous studies have shown various relationships 
between Vitamin-D and AITD [11].
This study was found that all GD patients 
were accompanied by Vitamin-D deficiency, where the 
Vitamin-D levels of all samples were <20 ng/mL or an 
average of 16 ng/mL in both treatment groups. As already 
explained, that Vitamin-D has immunomodulatory 
activity. Therefore, Vitamin-D can suppress the immune 
system in GD [5].
The study conducted in Hungary reported 
that there is association between hyperthyroidism 
and Vitamin-D found, where deficiency of Vitamin-D 
was significantly higher in patients with hyperthyroid 
(Vitamin-D levels <10 ng/mL) than in healthy people 
who were the same as age, as well as in patients 
with hyperthyroidism compared with patients with 
non-AITD [12]. The study conducted in Turkey is the 
only study conducted in the pediatric population, 
reported that higher levels of Vitamin-D deficiency 
(<15 ng/mL) in children with newly diagnosed 
hyperthyroidism compared to sex-appropriate control 
groups and age [13].
Hyperthyroidism in patients with GD is mainly 
due to the production of autoantibodies that bind to 
receptors for thyrotropin (TSH) in thyroid cells [5]. 
GD is the most common cause of hyperthyroidism 
in children and adolescents [14]. Thyrotoxicosis is a 
general term that indicates an increase in levels of T3 
(triiodothyronine) and or T4 (thyroxine) with any cause, 
whereas hyperthyroidism is a result of a thyrotoxicosis 
state due to increased thyroid hormone production [15].
In the present study, we sought to clarify whether 
supplemental administration of Vitamin-D influences the 
treatment course of patients with GD. We found that 
in patients who were treated with both methimazole 
and Vitamin-D supplement, FT4 was decrease more 
rapidly compared with the levels in patients treated with 
methimazole alone in the 2nd and 3rd months of therapy, 
although the difference in FT4 levels between the two 
groups was not significantly different. Serum levels of 
TSH showed a reciprocal increase, and the rate of this 
increase was more rapid in Group B. The rapid decrease 
of FT4 in Group I may, therefore, be due to decrease in 
thyroid hormone production by the addition of Vitamin-D 
supplement. However, the dose of methimazole in both 
groups is still in the therapeutic dose range, we cannot 
completely rule out the possibility that the physicians 
decreased methimazole doses more rapidly in patients 
treated with methimazole alone.
As described in the introduction, it has recently 
been shown that Vitamin-D has immunomodulatory 
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activity. However, TRAb values after treatment were 
not measured in our study. Study conducted in Japan 
assess the effect of Vitamin-D supplementation on 
GD reported that there were no differences in TRAb 
levels in patients who received methimazole alone 
or with Vitamin-D supplementation. There may be 
several possibilities for the mechanism of antithyroid 
action of Vitamin-D. The first is a decrease in TSH 
receptors numbers. The second is an acceleration in 
the metabolism or a decrease in the biosynthesis of 
thyroid hormones. The third is vitamin-D has a direct 
effect on TRAb. At this moment, we are uncertain as 
to which one is most likely. However, recent studies 
using cultured rat thyroid cells strongly suggest direct 
antithyroid action of vitamin-D [16].
This study has several weaknesses. First, 
we did not evaluate TRAb levels after Vitamin-D 
supplementation and also adjustment dosage of 
methimazole during the period of therapy, although 
the dosage of methimazole is still in the dosage range. 
Second, this study only assessed Vitamin-D, but no 
assessed about daily habits patients like exposed to 
sunlight as one of the main sources of Vitamin-D. Third, 
the subjects are too small so it is difficult to generalized. 
There is a need for multicenter advanced study with 
more subjects so that it can be applied to all children 
with GD.
Conclusion
Hyperthyroidism in patients with GD is mainly 
due to the production of autoantibodies that bind to TSH 
receptors on thyroid cells. Many studies have stated 
that low Vitamin-D status is a risk factor for autoimmune 
disease. In this study, we found that all children with GD 
had Vitamin-D deficiency, and the addition of Vitamin-D 
supplement to GD therapy would improve the thyroid 
profile of GD children faster than children with GD who 
did not receive Vitamin-D supplement. However, further 
research with large samples and long monitoring is 
needed to assess the effect of supplementation on the 
autoimmune disease process.
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